研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.[2]The First People's Hospital of Yunnan Province Kunming,Yunnan,China,650032[3]West China Hospital of Sichuan University Chengdu,Sichuan,China,610041[4]Jincheng Geberal Hospital Jincheng,Shanxi,China,048000[5]Yuncheng Central Hospital Jinan,Shandong,China,250000[6]Xiangya Hospital Central South University Changsha,Hunan,China,410008[7]The First Affiliated Hospital of Guangxi Medical University Nanning,Guangxi,China,530021[8]The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou,Guangdong,China,510630
研究目的：
TQ-F3083 capsule is a new type inhibitor of DPP-IV, which is currently a very effective target for the treatment of type 2 diabetes mellitus at clinical. In addition, it can promote insulin secretion with low potential toxicity, and half-life is shorter than Linagliptin.
